AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. (Currently amended) A nucleic acid molecule capable of binding to an envelope glycoprotein of an enveloped virus comprising the nucleic acid set forth in SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or combination thereof, wherein the binding of said nucleic acid molecule results in neutralizing said virus.
2. (Previously presented) The nucleic acid molecule of claim 1, wherein said virus is HIV.
3. (Previously presented) The nucleic acid molecule of claim 1, wherein said virus is HIV-1.
4. (Previously presented) The nucleic acid molecule of claim 1, wherein envelope glycoprotein is gp120.
5. (cancelled) The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises the nucleic acid set forth in SEQ ID NO. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or combination thereof.
6. (Previously presented) The nucleic acid molecule of claim 1, wherein said nucleic acid molecule further comprises modified pyrimidine or purine nucleotide bases.
7. (Currently amended) The modified nucleic acid molecule of claim 6, wherein said ~~pyrimidine~~ purine is modified in ~~the 6 or 8~~ the 2, 6, or 8 position of the purine ring.
8. (withdrawn) A method for screening for potential therapeutic targets utilizing the nucleic acid molecule of claim 5.
9. (withdrawn) The method of claim 8, wherein said method further comprising competitive inhibition.
10. (Currently amended) A pharmaceutical composition comprising the nucleic acid molecule of claim 1[[5]].
11. (Currently amended) A medicament for use in the treatment of HIV infection, comprising the nucleic acid of claim 1[[5]].

12. (withdrawn) A method for the treatment of HIV infection comprising administering an effective amount of the nucleic acid molecule as in claim 5 to a subject in need thereof.
13. (Currently amended) The modified nucleic acid molecule of claim 6, wherein said purine is modified in the [[5]] 2' carbon ribose ~~position~~.
14. (Currently amended) The modified nucleic acid molecule of claim 6, wherein said pyrimidine is modified in the [[2]] 2' carbon ribose ~~position~~.
15. (Currently amended) The modified nucleic acid molecule of claim 6 [[13]], wherein said pyrimidine ~~purine~~ is modified in the 5 or 6 position of the pyrimidine ring with –CH_3, I, Br, or Cl.
16. (Currently amended) The modified nucleic acid molecule of claim 14, wherein said pyrimidine is modified in the [[2]] 2' position with –NH_3, O^6-CH_3, N^6-CH_3 or N^2-CH_3.
17. (Currently amended) The modified nucleic acid molecule of claim 14, wherein said pyrimidine is modified in the [[2]] 2' position with NH_2, F or OCH_3.
18. (Previously presented) The pharmaceutical composition of claim 10, further comprising a pharmaceutically acceptable carrier, diluent or excipient.
19. (New) The modified nucleic acid molecule of claim 13, wherein said purine is modified in the 2' position with NH_2, F or OCH_3.